Abeona TherapeuticsNASDAQ: ABEO

NEW YORK , June 7, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext. 7980.

NEW YORK , May 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

NEW YORK , May 23, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Pomerantz LLP is currently looking into allegations involving investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO) and is encouraging these investors to reach out to Danielle Peyton at [email protected] or 646-581-9980, ext.

Abeona Therapeutics is a gene therapy company developing Pz-cel as a treatment for RDEB, a severe skin condition. Pz-cel has demonstrated superior effectiveness in treating large skin lesions compared to other treatments. While the FDA issued a complete response letter, Abeona is confident in resolving manufacturing issues and aims to submit a response by Q3.

Abeona Therapeutics Inc shares jumped 15% to $4.96 in late-morning trading on Monday after the US Food and Drug Administration (FDA) said it would expedite a review of pz-cel (prademagene zamikeracel), the company's proposed treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB), a rare, inherited connective-tissue disorder.   The clinical-stage biopharmaceutical company had previously stated that it expected an FDA decision on priority-review status by late November.

Investing in undervalued penny stocks is always going to be about the same few things. Most investors are attempting to find cheap, short-term plays with reasonable catalysts in their favor.

Investing in biotech stock can provide investors with immense rewards but also substantial risks. The key is finding the right balance.